TME Pharma N.V. (EPA:ALTME)
France
· Delayed Price · Currency is EUR 0.0644
-0.0016 (-2.42%)
Apr 24, 2025, 3:46 PM CET
TME Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2014 - 2018 |
| Other Revenue | - | - | - | 0.03 | 0.04 | 0.15 | Upgrade
|
| Revenue | - | - | - | 0.03 | 0.04 | 0.15 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | -5.71% | -77.27% | - | Upgrade
|
| Gross Profit | - | - | - | 0.03 | 0.04 | 0.15 | Upgrade
|
| Selling, General & Admin | 3.16 | 2.99 | 3.88 | 2.88 | 1.88 | 2.12 | Upgrade
|
| Research & Development | 2.44 | 2.65 | 8.15 | 10.66 | 4.02 | 2.11 | Upgrade
|
| Other Operating Expenses | 0.01 | -0.02 | -0.02 | -0.04 | -0.04 | -0.01 | Upgrade
|
| Operating Expenses | 5.61 | 5.62 | 12.01 | 13.49 | 5.86 | 4.22 | Upgrade
|
| Operating Income | -5.61 | -5.62 | -12.01 | -13.46 | -5.82 | -4.06 | Upgrade
|
| Interest Expense | - | -0.02 | -0.13 | -0.05 | -0.13 | -0 | Upgrade
|
| Interest & Investment Income | 0.02 | - | - | - | - | 0.08 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.03 | 0.01 | -0.03 | 0.18 | 0.01 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.84 | -1.34 | -3.27 | -1.42 | -4.92 | 3.01 | Upgrade
|
| EBT Excluding Unusual Items | -6.4 | -6.97 | -15.45 | -14.74 | -10.86 | -0.98 | Upgrade
|
| Other Unusual Items | 0.07 | 0.24 | 0.32 | 0.29 | 0.45 | 0.12 | Upgrade
|
| Pretax Income | -6.32 | -6.73 | -15.13 | -14.45 | -10.41 | -0.86 | Upgrade
|
| Income Tax Expense | 0 | 0 | 0.01 | 0 | - | 0 | Upgrade
|
| Earnings From Continuing Operations | -6.33 | -6.74 | -15.13 | -14.45 | -10.41 | -0.86 | Upgrade
|
| Minority Interest in Earnings | - | - | 0 | 0 | 0 | - | Upgrade
|
| Net Income | -6.33 | -6.74 | -15.13 | -14.45 | -10.41 | -0.86 | Upgrade
|
| Net Income to Common | -6.33 | -6.74 | -15.13 | -14.45 | -10.41 | -0.86 | Upgrade
|
| Shares Outstanding (Basic) | 17 | 5 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 17 | 5 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 606.13% | 326.62% | 78.28% | 103.92% | 190.00% | 180.42% | Upgrade
|
| EPS (Basic) | -0.37 | -1.34 | -12.86 | -21.90 | -32.16 | -7.72 | Upgrade
|
| EPS (Diluted) | -0.37 | -1.34 | -12.86 | -21.90 | -32.16 | -7.72 | Upgrade
|
| Free Cash Flow | -4.98 | -5.65 | -12.16 | -12.4 | -5.26 | -4.3 | Upgrade
|
| Free Cash Flow Per Share | -0.29 | -1.13 | -10.34 | -18.79 | -16.27 | -38.55 | Upgrade
|
| Gross Margin | - | - | - | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | - | - | - | -40790.91% | -16640.00% | -2638.96% | Upgrade
|
| Profit Margin | - | - | - | -43793.94% | -29728.57% | -559.09% | Upgrade
|
| Free Cash Flow Margin | - | - | - | -37560.61% | -15037.14% | -2793.51% | Upgrade
|
| EBITDA | -5.59 | -5.59 | -11.99 | -13.44 | -5.81 | -4.04 | Upgrade
|
| D&A For EBITDA | 0.02 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | Upgrade
|
| EBIT | -5.61 | -5.62 | -12.01 | -13.46 | -5.82 | -4.06 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.